GIS — General Mills, Inc.

The market is cautious, not panicked: Wall Street ratings are 8 buys, 22 holds, and 6 sells, with a consensus target near $35, while the stock has bounced from $31.75 lows to $40.44 and RSI sits at 62.8. Income investors like the high dividend yield, but volume declines, GLP-1 fears, and a heavy balance sheet keep a lid on enthusiasm.

Revenue has declined in both visible fiscal years: FY25 was $19.49B (-1.9% vs FY24) and FY26 was $18.42B (-5.4% vs FY25; organic -2%). The trend stabilized in Q4 FY26, with sales up ~1% YoY to $4.61B after declines in the prior three quarters. Reported TTM operating margin of 20% is flattered by an unusual $1.73B operating-income line in Q1 FY26 that exceeded that quarter's gross profit; normalizing for that one-off puts recurring operating margin closer to 15%. GAAP TTM EPS of -$0.16 is distorted by a large Q4 charge; adjusted FY26 EPS was $3.55, and consensus FY27 EPS is $3.08, implying another year of earnings decline.

The stock looks cheap versus its own history: TTM P/E is negative and meaningless, forward P/E is ~13.1x on FY27 EPS of $3.08, below the 5-year average of 15.9x, and price/sales of 1.17x is well below the 5-year average of 1.85x. The catch is the balance sheet (D/E 1.84x, current ratio 0.68x) and the forecast EPS decline, so this is 'cheap for a reason' rather than an unequivocal bargain. At a 6-6.7% dividend yield with stable free cash flow, valuation is fair with a modest income floor.

At $40.44 the market is already pricing in no growth and further EPS erosion. If management delivers the $750M FY27 cost savings and stabilizes organic volumes, normalized EPS could hold near $3.50, making the stock worth $45+ at a still-modest 13x. If volumes keep falling and EPS drops toward $2.80, the current multiple is really ~14.4x and the stock is not cheap. This is a show-me setup: don't extrapolate the low P/E without evidence that margins inflect.

As of 2026-08-27, RSI is 62.79, price is 5.7% above the 20-day average, 9.1% above the 50-day average, and 0.8% above the 200-day average. That is a short-term rebound within a longer downtrend, not an oversold bottom; the stock sits right at its 200-day moving average, roughly $40.10, a key pivot. A decisive close above that level would signal base-building, while losing the 50-day area near $37 could retest the lower end of the range.

• Value-conscious consumers and private-label substitution continue to pressure branded food volumes; FY26 organic sales were -2%.
• GLP-1/weight-loss drugs are a structural overhang for indulgent packaged-food categories.
• High leverage ($12.4B long-term debt, D/E 1.84x) and a current ratio of 0.68x make interest rates and refinancing a real sensitivity.
• U.S.-Canada trade friction and input-cost inflation could squeeze margins and make price investments harder to fund.
• Defensive rotation into high-dividend staples provides intermittent support when consumer confidence and macro volatility worsen.

• Q1 FY2027 earnings on Sept 23, 2026 - the first real check on organic volume and cost-savings execution.
• Cost-savings roadmap: $3B cumulative by FY2030, with $750M targeted in FY27; early margin evidence could re-rate the stock.
• Portfolio simplification and debt paydown from exits such as Häagen-Dazs operations in China and Brazil.
• Cereal innovation and artificial-color removal across the U.S. cereal portfolio, aimed at stabilizing base volumes.

• Persistent volume/market-share losses to private label and promotions; another organic-sales decline would break the turnaround story.
• Balance-sheet risk: $12.4B long-term debt, D/E 1.84x, current ratio 0.68x, and dividends absorbing much of free cash flow.
• Structural category risk from GLP-1 usage reducing demand for indulgent foods.
• Management's price investments fail to defend volume and instead compress gross margin below 33%.

General Mills is a high-yield, low-growth defensive business that the market already prices as such. At $40.44 you're paid ~6% to wait, but the bull case depends on $3B of cost savings offsetting a -2% organic-volume backdrop; the bear case is leverage and structural category decline. I view it as a hold/income vehicle, not a compelling buy, and would want either a pullback toward the $37-38 area or visible volume/margin inflection before adding.

Calculated by applying a 12.5x multiple to consensus forward FY27 EPS of $3.08 - a justified discount to the 15.9x 5-year average P/E because organic sales are declining, FY27 EPS is expected to fall, and the balance sheet is leveraged. The 6%+ dividend yield provides a floor near this level, so fair value lands at $38.53, slightly below the current $40.44 quote.